| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary targets of monogalactosyl diglyceride are bacteria and fungi. The compound has antibacterial and antifungal activity. Monogalactosyl diglyceride has also been shown to stimulate PKCα activity in oligodendrocytes. The compound may have protective effects against oxidative stress-related diseases such as liver and DNA damage.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the antimicrobial activity of monogalactosyl diglyceride. The compound has antibacterial and antifungal activity. Monogalactosyl diglyceride has been shown to stimulate PKCα activity in oligodendrocytes. Its in vitro activities support its potential for further investigation.
|
| ln Vivo |
In vivo activity of monogalactosyl diglyceride has been studied in the context of its protective effects against oxidative stress-related diseases. The compound may protect against liver and DNA damage. Specific in vivo data have been reported in the literature. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
For antimicrobial activity screening, standard agar diffusion or broth microdilution methods are used. Bacteria and fungi are cultured on appropriate media and exposed to serial dilutions of monogalactosyl diglyceride. MIC values are determined after 24-48 hours of incubation. Standard protocols for antimicrobial activity testing are described in the literature.
|
| Cell Assay |
For in vitro cell-based studies, bacterial and fungal cells are cultured in appropriate media and treated with serial dilutions of monogalactosyl diglyceride. Cell growth is assessed. For PKCα activity studies, oligodendrocytes are treated with the compound and PKCα activity is measured.
|
| Animal Protocol |
In vivo animal studies for monogalactosyl diglyceride have been conducted in models of oxidative stress-related diseases. The compound's protective effects against liver and DNA damage have been evaluated. Standard protocols for in vivo efficacy studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of monogalactosyl diglyceride have not been extensively characterized. As a glycolipid with a high molecular weight of 787.16 g/mol, it may have limited oral bioavailability. The compound is typically stored as a powder at -20°C. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for monogalactosyl diglyceride are limited. As a natural glycolipid, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. The compound is for research use only.
|
| References | |
| Additional Infomation |
Monogalactosyl diglyceride is a research compound used in studies of galactolipids and their biological activities. It is a major component of photosynthetic membranes and a marker for myelination. The compound has antimicrobial activity and stimulates PKCα activity. No clinical trials or therapeutic applications have been reported.
|
| Molecular Formula |
C45H86O10
|
|---|---|
| Molecular Weight |
787.16
|
| Exact Mass |
786.622
|
| CAS # |
41670-62-6
|
| PubChem CID |
193820
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
826.4±65.0 °C at 760 mmHg
|
| Flash Point |
226.6±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.502
|
| LogP |
14.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
55
|
| Complexity |
873
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@H]([C@@H]([C@H]([C@H]([C@H]1CO)O)O)O)OCC(COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O
|
| InChi Key |
DCLTVZLYPPIIID-XMGVTQGESA-N
|
| InChi Code |
InChI=1S/C45H86O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h38-39,42-46,49-51H,3-37H2,1-2H3/t38?,39-,42+,43+,44-,45-/m1/s1
|
| Chemical Name |
[2-octadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] octadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2704 mL | 6.3519 mL | 12.7039 mL | |
| 5 mM | 0.2541 mL | 1.2704 mL | 2.5408 mL | |
| 10 mM | 0.1270 mL | 0.6352 mL | 1.2704 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
